AnthologyRX
Injection

GHK-Cu / Epithalon

A compounded GHK-Cu and Epithalon prescription pairing connective-tissue biology with a defined short-peptide longevity thesis.

Your treatment plan

From $179/month

$537 billed every 3 months3-month commitmentView plan details
Start assessment
  • Licensed clinicians
  • Compounded by a licensed 503A pharmacy
  • No clinic visit

Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.

Important safety information
What It Is

Structure ages too.

Longevity plans are very good at talking about energy, hormones, glucose, and numbers on a lab report. The quieter part is the physical structure underneath all of it: skin, connective tissue, and the extracellular matrix that gives tissue its architecture even when there is no injury to repair.

That is the lane this combination is built to occupy.

GHK-Cu is the three-amino-acid GHK peptide carrying copper. In fibroblast cultures, research shows GHK-Cu stimulates collagen synthesis1 and increases matrix metalloproteinase-2 expression, a process involved in extracellular-matrix remodeling.2 Epithalon is the defined four-amino-acid AEDG peptide studied in short-peptide signaling and gene regulation.3

The pairing is intentionally asymmetric. GHK-Cu brings specific cell-level findings in connective-tissue and matrix biology. Epithalon brings broader research around a defined short peptide. They do not have to carry the same evidence weight for your clinician to evaluate the biological pairing.

The two signals enter from different directions: GHK-Cu through connective-tissue and extracellular-matrix research, and Epithalon through defined short-peptide aging research. Together they give your clinician two distinct biological tracks to evaluate in one systemic plan.

  1. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the… FEBS Lett. 1988.PubMed
  2. Maquart FX, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+… Life Sci. 2000.PubMed
  3. Araj SK, et al. Overview of Epitalon, Highly Bioactive Pineal Tetrapeptide with… Int J Mol Sci. 2025.PubMed
Who It's For

For the part of longevity you cannot see on a metabolic panel.

01

The Structural Thinker

You are not treating a fresh injury and you are not shopping for a cosmetic promise. You are thinking about the tissue itself as part of how the body changes over time.

02

The GHK-Cu Reader

You know the copper-peptide name already, usually from the topical world. What you want now is a medically serious conversation about the systemic version, including copper handling and your full health history.

03

The Plan Beyond the Basics

Metabolic and hormonal fundamentals are already being addressed. The next layer you want evaluated is the connective tissue and matrix biology those conversations tend to leave out.

Injectable GHK-Cu was removed from FDA Category 2 in April 2026 with further review docketed before February 28, 2027; removal from Category 2 does not itself make it eligible for 503A compounding or place it in Category 1 enforcement discretion. Epitalon, the same AEDG tetrapeptide sold here as Epithalon, received a favorable 7-5-1 PCAC recommendation in July 2026, but that recommendation is advisory and FDA has not acted. Neither fact is an FDA approval. The preparation offered here is compounded and not FDA approved.

This might not be the right fit if:
  • You have Wilson disease or another disorder of copper metabolism.
  • You use significant supplemental copper that has not been reviewed by your provider.
  • You have active or recent cancer without oncology clearance.
  • You are pregnant or breastfeeding.
  • You have a known hypersensitivity to any component of the preparation.
  • You are under 18.

Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.

Your Plan

GHK-Cu / Epithalon, prescribed with care.

Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.

One price covers the provider, the prescription if approved, the pharmacy, and the follow-up.
Compounded by a licensed 503A pharmacy
GHK-Cu / Epithalon
Injection
From $179
Per month, all-inclusive. If approved by your provider*

3-month commitment

  • An independent licensed provider reviews your full Assessment and gives you a real answer either way.
  • Copper exposure, medications, and relevant medical history are reviewed before treatment is prescribed.
  • If approved, your dose and duration are set for you, with follow-up built into your care.
  • Provider review, the prescription if approved, pharmacy, and shipping handled inside one plan.
$179 /mo · 3-month commitment
$179/mo, all-in. Provider review, prescription if approved, pharmacy fulfillment. Consultation and refund terms.
Start assessment

Compounded by a licensed US pharmacy to an individual prescription. Compounded preparations are not FDA-approved drug products.

*Price reflects a 3 month commitment. Other billing options are shown at checkout.

Important Safety Information

Serious risks

  • Wilson disease and other disorders of copper handling matter, as does supplemental copper from other products, because GHK-Cu carries copper
  • Laboratory research has examined telomerase and telomere effects, including findings in cancer cell lines
  • Active or recent malignancy deserves specific review
  • Pregnancy and breastfeeding safety are not established

Because it is injectable

  • Injection-site reactions are possible

This combination has not been established as a finished drug product in controlled human trials. Human systemic safety data for injectable GHK-Cu are limited. Epithalon also has limited long-term human safety data. That does not establish a cancer effect in people. Your provider reviews these uncertainties before prescribing the combination.

  1. Al-Dulaimi S, et al. Epitalon increases telomere length in human cell lines through… Biogerontology. 2025.PubMed
Questions

Asked and answered.

If your provider determines you are not a candidate for any available treatment, any consultation fee paid will be refunded within 7–10 business days. You are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.

No. GHK-Cu is familiar from skin and cosmetic products, but the reason it appears here is the underlying connective-tissue and extracellular-matrix biology. Changes in wrinkles, firmness, appearance, or another cosmetic outcome are not promised. Whether systemic treatment belongs in your plan is determined from your full Assessment.

One component, Epitalon, received a favorable PCAC recommendation in July 2026 for possible inclusion on the 503A Bulks List, while injectable GHK-Cu is under a separate FDA review pathway after removal from Category 2. Neither action is an FDA approval, and neither makes this combination an approved finished drug product. No compounded medication is FDA-approved, including this one. Compounded medicines are made to your individual prescription by a licensed pharmacy rather than manufactured and approved as a finished drug product.

Because they enter the longevity conversation from different directions. GHK-Cu has published cell and connective-tissue research showing collagen synthesis and extracellular-matrix remodeling activity.12 Epithalon is a defined AEDG tetrapeptide studied in broader short-peptide and aging-related research.3 The combination puts those two research tracks into one clinician-reviewed plan without pretending they carry the same evidence weight.

Enough that it belongs in the medical review. GHK-Cu carries a copper ion, and copper handling is tightly regulated by the body. Wilson disease and other copper-metabolism disorders can make extra copper exposure inappropriate. Tell your provider about copper-containing supplements, multivitamins, and any history of abnormal copper or liver testing before treatment is considered.

The appeal of a sophisticated combination is exactly why the care around it matters. Here, a licensed provider reviews the full two-component prescription, including copper exposure and medical history, and a licensed US pharmacy compounds it for you. The FDA has found products sold as research chemicals under false labels, some naming compounding pharmacies that do not exist, and warns they “can pose risks of serious harm” by bypassing the body’s defenses.F4 Testing has found wide variation in purity and in how much of the compound is actually in the vial. AnthologyRX is not asking you to trust a molecule because it sounds advanced. It is putting advanced biology inside a medical system accountable for whether it belongs in your care.

  1. Maquart FX, et al. Stimulation of collagen synthesis in fibroblast cultures by the… FEBS Lett. 1988.PubMed
  2. Maquart FX, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+… Life Sci. 2000.PubMed
  3. Araj SK, et al. Overview of Epitalon, Highly Bioactive Pineal Tetrapeptide with… Int J Mol Sci. 2025.PubMed
  4. FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, and FDA Warning Letter to Gram Peptides, March 31, 2026.
Explore

More in Longevity.

$179/mo3-month commitmentGHK-Cu / Epithalon
Start assessment

AnthologyRX is a technology and care-coordination platform, not a licensed pharmacy or medical provider. Clinical services are provided by independent licensed providers affiliated with Arora Health & Aesthetics, LLC, subject to their individual clinical judgment. Medications are dispensed or compounded by licensed pharmacies, including licensed 503A compounding pharmacies. Compounded medications are not FDA-approved drug products and have not been evaluated by the FDA for safety, efficacy, or quality. Brand names, where shown, identify the reference product only; AnthologyRX is not affiliated with their manufacturers. Individual results vary. No outcome is guaranteed. AnthologyRX does not provide medical advice and does not treat, cure, or prevent any disease. All treatments are subject to provider evaluation and approval. Available in all 50 U.S. states; availability of specific medications and formats varies by state. FSA/HSA eligibility varies by plan. AnthologyRX is not a replacement for primary or emergency medical care. Product images are illustrative. Packaging may vary by pharmacy and prescription. © 2026 AnthologyRX. All rights reserved.

AnthologyRX
Find your treatment
Browse all treatments